Report Detail
Global Parkinson's Disease (PD) Drugs Market Insights, Forecast to 2025
- RnM2799958 |
- 19 June, 2019 |
- Global |
- 127 Pages |
- QYResearch |
- Pharma & Healthcare
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.
The global Parkinson's Disease (PD) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Parkinson's Disease (PD) Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Parkinson's Disease (PD) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Parkinson's Disease (PD) Drugs in these regions.
This research report categorizes the global Parkinson's Disease (PD) Drugs market by top players/brands, region, type and end user. This report also studies the global Parkinson's Disease (PD) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
Market size by Product
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Market size by End User
Hospital
Family
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Parkinson's Disease (PD) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Parkinson's Disease (PD) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Parkinson's Disease (PD) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Parkinson's Disease (PD) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Parkinson's Disease (PD) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Parkinson's Disease (PD) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Parkinson's Disease (PD) Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by Product
- 1.4.2 Dopamine Agonist
- 1.4.3 Monoamine Oxidase Inhibitors
- 1.4.4 Acetylcholinesterase Inhibitors
- 1.4.5 Glutamate Inhibitors
- 1.5 Market by End User
- 1.5.1 Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Family
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Parkinson's Disease (PD) Drugs Market Size
- 2.1.1 Global Parkinson's Disease (PD) Drugs Revenue 2014-2025
- 2.1.2 Global Parkinson's Disease (PD) Drugs Sales 2014-2025
- 2.2 Parkinson's Disease (PD) Drugs Growth Rate by Regions
- 2.2.1 Global Parkinson's Disease (PD) Drugs Sales by Regions
- 2.2.2 Global Parkinson's Disease (PD) Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers
- 3.1.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers
- 3.1.2 Parkinson's Disease (PD) Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Parkinson's Disease (PD) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Parkinson's Disease (PD) Drugs Revenue by Manufacturers
- 3.2.1 Parkinson's Disease (PD) Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Parkinson's Disease (PD) Drugs Price by Manufacturers
- 3.4 Parkinson's Disease (PD) Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Parkinson's Disease (PD) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Parkinson's Disease (PD) Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Parkinson's Disease (PD) Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Parkinson's Disease (PD) Drugs Sales by Product
- 4.2 Global Parkinson's Disease (PD) Drugs Revenue by Product
- 4.3 Parkinson's Disease (PD) Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Parkinson's Disease (PD) Drugs Breakdown Data by End User
6 North America
- 6.1 North America Parkinson's Disease (PD) Drugs by Countries
- 6.1.1 North America Parkinson's Disease (PD) Drugs Sales by Countries
- 6.1.2 North America Parkinson's Disease (PD) Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Parkinson's Disease (PD) Drugs by Product
- 6.3 North America Parkinson's Disease (PD) Drugs by End User
7 Europe
- 7.1 Europe Parkinson's Disease (PD) Drugs by Countries
- 7.1.1 Europe Parkinson's Disease (PD) Drugs Sales by Countries
- 7.1.2 Europe Parkinson's Disease (PD) Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Parkinson's Disease (PD) Drugs by Product
- 7.3 Europe Parkinson's Disease (PD) Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Parkinson's Disease (PD) Drugs by Countries
- 8.1.1 Asia Pacific Parkinson's Disease (PD) Drugs Sales by Countries
- 8.1.2 Asia Pacific Parkinson's Disease (PD) Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Parkinson's Disease (PD) Drugs by Product
- 8.3 Asia Pacific Parkinson's Disease (PD) Drugs by End User
9 Central & South America
- 9.1 Central & South America Parkinson's Disease (PD) Drugs by Countries
- 9.1.1 Central & South America Parkinson's Disease (PD) Drugs Sales by Countries
- 9.1.2 Central & South America Parkinson's Disease (PD) Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Parkinson's Disease (PD) Drugs by Product
- 9.3 Central & South America Parkinson's Disease (PD) Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Parkinson's Disease (PD) Drugs by Countries
- 10.1.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Countries
- 10.1.2 Middle East and Africa Parkinson's Disease (PD) Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Parkinson's Disease (PD) Drugs by Product
- 10.3 Middle East and Africa Parkinson's Disease (PD) Drugs by End User
11 Company Profiles
- 11.1 Boehringer Ingelheim
- 11.1.1 Boehringer Ingelheim Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Products Offered
- 11.1.5 Boehringer Ingelheim Recent Development
- 11.2 GlaxoSmithKline
- 11.2.1 GlaxoSmithKline Company Details
- 11.2.2 Company Business Overview
- 11.2.3 GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 GlaxoSmithKline Parkinson's Disease (PD) Drugs Products Offered
- 11.2.5 GlaxoSmithKline Recent Development
- 11.3 Novartis
- 11.3.1 Novartis Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Novartis Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Novartis Parkinson's Disease (PD) Drugs Products Offered
- 11.3.5 Novartis Recent Development
- 11.4 Teva Pharmaceutical Industries
- 11.4.1 Teva Pharmaceutical Industries Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Products Offered
- 11.4.5 Teva Pharmaceutical Industries Recent Development
- 11.5 AbbVie
- 11.5.1 AbbVie Company Details
- 11.5.2 Company Business Overview
- 11.5.3 AbbVie Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 AbbVie Parkinson's Disease (PD) Drugs Products Offered
- 11.5.5 AbbVie Recent Development
- 11.6 Abital Pharma
- 11.6.1 Abital Pharma Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Abital Pharma Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Abital Pharma Parkinson's Disease (PD) Drugs Products Offered
- 11.6.5 Abital Pharma Recent Development
- 11.7 Addex Therapeutics
- 11.7.1 Addex Therapeutics Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Addex Therapeutics Parkinson's Disease (PD) Drugs Products Offered
- 11.7.5 Addex Therapeutics Recent Development
- 11.8 Biogen
- 11.8.1 Biogen Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Biogen Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Biogen Parkinson's Disease (PD) Drugs Products Offered
- 11.8.5 Biogen Recent Development
- 11.9 Eisai
- 11.9.1 Eisai Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Eisai Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Eisai Parkinson's Disease (PD) Drugs Products Offered
- 11.9.5 Eisai Recent Development
- 11.10 Eli Lilly
- 11.10.1 Eli Lilly Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Eli Lilly Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Eli Lilly Parkinson's Disease (PD) Drugs Products Offered
- 11.10.5 Eli Lilly Recent Development
- 11.11 F. Hoffmann-La Roche
- 11.12 H. Lundbeck
- 11.13 Impax Laboratories
- 11.14 Kyowa Hakko Kirin
- 11.15 Otsuka Pharmaceutical
- 11.16 Pfizer
12 Future Forecast
- 12.1 Parkinson's Disease (PD) Drugs Market Forecast by Regions
- 12.1.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Parkinson's Disease (PD) Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Parkinson's Disease (PD) Drugs Market Forecast by Product
- 12.2.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Parkinson's Disease (PD) Drugs Revenue Forecast by Product 2019-2025
- 12.3 Parkinson's Disease (PD) Drugs Market Forecast by End User
- 12.4 North America Parkinson's Disease (PD) Drugs Forecast
- 12.5 Europe Parkinson's Disease (PD) Drugs Forecast
- 12.6 Asia Pacific Parkinson's Disease (PD) Drugs Forecast
- 12.7 Central & South America Parkinson's Disease (PD) Drugs Forecast
- 12.8 Middle East and Africa Parkinson's Disease (PD) Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Parkinson's Disease (PD) Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Parkinson's Disease (PD) Drugs . Industry analysis & Market Report on Parkinson's Disease (PD) Drugs is a syndicated market report, published as Global Parkinson's Disease (PD) Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Parkinson's Disease (PD) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
